| Patents for A61K 41 - Medicinal preparations obtained by treating materials with wave energy or particle radiation (9,445) |
|---|
| 11/15/2001 | WO2001085213A2 Supports for photosensitizer formulations |
| 11/15/2001 | WO2001085212A2 Drug delivery systems for photodynamic therapy |
| 11/15/2001 | WO2001085211A1 Regeneration of cells in pathogenic organs |
| 11/15/2001 | WO2001085202A2 Electroporation for introduction of molecules into cells |
| 11/15/2001 | WO2001085190A1 Irradiation of ispaghula |
| 11/15/2001 | WO2001085185A2 Treatment of il-10 deficiencies |
| 11/15/2001 | US20010041713 Cyclooxygenase-2 (COX-2); administering 2-(2-methylpyrid-5-yl),3-(p-methylsulfonylphenyl),5-chloro-pyridine, or salt, hydrate or N-oxide thereof, alone or in combination with other drugs |
| 11/15/2001 | CA2407743A1 Irradiation of ispaghula |
| 11/15/2001 | CA2379088A1 Treatment of il-10 deficiencies |
| 11/14/2001 | EP1152772A2 Liposome composition and method for administration of a radiosensitizer |
| 11/14/2001 | CN1322136A Neuroimmunophilins for selective neuronal radioprotection |
| 11/14/2001 | CN1074665C Method and medical agent for diagnosis and/or therapy of arthritis |
| 11/13/2001 | US6316007 Combined physical and immunotherapy for cancer |
| 11/13/2001 | US6315981 Used for obtaining image of an internal region of humans |
| 11/13/2001 | US6315978 Bioconjugates and delivery of bioactive agents |
| 11/13/2001 | US6315730 Ultrasound imaging of tissue perfusion by pulse energy disruption of contrast agent |
| 11/11/2001 | CA2308105A1 Treatment of il-10 deficiencies |
| 11/08/2001 | WO2001082899A2 Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites |
| 11/08/2001 | WO2001082860A2 Use of ursodeoxycholic acid for potentiation of the phototoxic effect of photodynamic therapy |
| 11/08/2001 | WO2001082859A2 Method for producing r-teatrol analogs having an antineoplastic activity |
| 11/08/2001 | US20010039438 Method for treating neovascularization |
| 11/08/2001 | DE10020935A1 Verwendung von Photofrin als Radiosensitizer Using Photofrin as a radiosensitizer |
| 11/06/2001 | US6312697 Inhibitory effect of synthetic and natural colorants on carcinogenesis |
| 11/01/2001 | WO2001081360A1 Novel, photo-labile cumarinylmethyl esters of cyclic nucleotides, method for the production and use thereof |
| 11/01/2001 | WO2001080888A2 Method for treatment of tumors using photodynamic therapy |
| 11/01/2001 | US20010037080 Photoatherolytic catheter apparatus and method |
| 11/01/2001 | CA2407336A1 Method for treatment of tumors using photodynamic therapy |
| 10/31/2001 | EP1149584A1 Use of Photofrin as radiosensitizer |
| 10/31/2001 | EP1149057A1 Biodegradable glass compositions and methods for radiation therapy |
| 10/31/2001 | EP1148885A1 Electrically-mediated enhancement of dna vaccine immunity and efficacy in vivo |
| 10/31/2001 | DE10021256A1 Neue, photolabile Cumarinylmethylester von cyclischen Nucleotiden, Verfahren zu deren Herstellung und ihre Verwendung New photolabile coumarinylmethyl esters of cyclic nucleotides, processes for their preparation and their use |
| 10/31/2001 | CN1319431A Method for improving antitumor activity of amarogentin substance and its composition and evaluation method |
| 10/25/2001 | WO2001078606A1 Selective nuclear receptor-targeted systems for delivery of cytotoxins to cancer cells for targeted photodynamic therapy |
| 10/25/2001 | WO2001024684A3 Methods for treatment of solid tumors and metastasis by gene therapy |
| 10/25/2001 | WO2000062788A9 Treatment of hypersensitivity reaction disorders |
| 10/25/2001 | WO2000051639A9 Treatment of neoplastic diseases by radiation |
| 10/25/2001 | US20010034363 Water soluble paclitaxel derivatives |
| 10/24/2001 | EP1148058A1 Porphyrin compound |
| 10/24/2001 | EP1148057A1 Nitroimidazole-supporting porphyrin complex |
| 10/24/2001 | EP1146912A1 Method for improved radiation therapy |
| 10/24/2001 | EP0633027B1 Compound for the biological stimulation and correction of the phenotype of an organism and a process for producing the same |
| 10/23/2001 | US6306367 Fluorescent conjugate for differentiating between diseased and healthy tissues |
| 10/18/2001 | WO2001077301A1 Tumor cells transformation process |
| 10/18/2001 | WO2001077114A1 Inhibitors of prenyl-protein transferase |
| 10/18/2001 | WO2001076694A1 Inhibitors of prenyl-protein transferase |
| 10/18/2001 | WO2001076693A1 Inhibitors of prenyl-protein transferase |
| 10/18/2001 | WO2001076595A1 Intracorporeal medicaments for high energy phototherapeutic treatment of disease |
| 10/18/2001 | WO2001026704A3 Targeted drug activation |
| 10/18/2001 | US20010031740 Mixture containing organic halide |
| 10/18/2001 | US20010031243 Novel methods of ultrasound treatment using gas or gaseous precursor-filled compositions |
| 10/18/2001 | CA2405554A1 Intracorporeal medicaments comprising halogenated xanthenes for high energy phototherapeutic treatment of disease |
| 10/17/2001 | EP1146046A2 Pyropheophorbides and their use in photodynamic therapy |
| 10/17/2001 | CN1317951A Treatment of pigmented tissues using optical energy |
| 10/11/2001 | WO2001074818A1 Chlorins with fused rings for use in photodynamic therapy |
| 10/11/2001 | WO2001074398A1 Photodynamic therapy compounds |
| 10/11/2001 | WO2001074389A2 Improved treatment of neovascularization |
| 10/11/2001 | WO2001074369A1 Divided dose therapies with vascular damaging activity |
| 10/11/2001 | WO2001074368A1 Combination therapies with vascular damaging activity |
| 10/11/2001 | WO2001074346A2 Sensitization of cells to cytotoxic agents using oligonucleotides directed to nucleotide excision repair or transcritpion coupled repair genes |
| 10/11/2001 | WO2001074342A2 Use of locally applied dna fragments |
| 10/11/2001 | WO2000045823A9 Electrically-mediated enhancement of dna vaccine immunity and efficacy in vivo |
| 10/11/2001 | CA2405549A1 Sensitization of cells to cytotoxic agents using oligonucleotides directed to nucleotide excision repair or transcription coupled repair genes |
| 10/11/2001 | CA2403612A1 Improved treatment of neovascularization |
| 10/11/2001 | CA2402539A1 Combination therapies with vascular damaging activity |
| 10/11/2001 | CA2402078A1 Divided dose therapies with vascular damaging activity |
| 10/11/2001 | CA2376001A1 Photodynamic therapy compounds |
| 10/10/2001 | EP1140290A2 Synergistic tumorcidal response induced by histamine |
| 10/10/2001 | EP1140194A2 Use of cyclooxygenase-2 inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combined treatment of neoplasia |
| 10/10/2001 | EP1140193A2 Use of an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| 10/10/2001 | EP1140192A2 Use of a cyclooxygenase-2 inhibitor and one or more antineoplastic agents for combination therapy in neoplasia |
| 10/10/2001 | EP1140183A1 Use of a matrix metalloproteinase inhibitor and an integrin antagonist in the treatment of neoplasia |
| 10/10/2001 | EP1140182A2 Use of a matrix metalloproteinase inhibitor together with an antineoplastic agent, optionally also together with radiation, in the treatment of neoplasia |
| 10/10/2001 | EP1140181A1 Combination therapy of radiation and a cox-2 inhibitor for the treatment of neoplasia |
| 10/10/2001 | EP1140180A2 Targeting of sebaceous follicles as a treatment of sebaceous gland disorders |
| 10/10/2001 | EP1140179A2 Use of a cyclooxygenase 2 inhibitor and an integrin antagonist as a combination therapy in the treatment of neoplasia |
| 10/10/2001 | EP1140178A2 Use of a matrix metallaproteinase inhibitor and radiation as a combined treatment of neoplasia |
| 10/10/2001 | EP1140177A2 Use of an integrin antagonist and radiation in the treatment of neoplasia |
| 10/10/2001 | EP1140176A1 Transcutaneous photodynamic treatment of targeted cells |
| 10/09/2001 | US6299873 Surgical removal or reduction of body burden of malignant cells and retention of some of those cells for subsequent use in immunotherapy; boron neutron-capture therapy is employed at radiation dosage below threshold for normal tissue necrosis |
| 10/09/2001 | US6299856 Introducing, at or near site of said malignancy, collagen covalently linked to a radioactive isotope or stable element subsequently activated to become radioactive isotope, in an effective amount to inhibit or reverse malignancy |
| 10/04/2001 | WO2001072721A2 Synergistic methods and compositions for treating cancer |
| 10/04/2001 | WO2001072301A1 Intracorporeal medicaments for photodynamic treatment of disease |
| 10/04/2001 | WO2001032070A3 Reagents and methods for diagnosing, imaging and treating atherosclerotic disease |
| 10/04/2001 | US20010026812 Method for determining the three-dimensional structure of a protein |
| 10/04/2001 | US20010025919 Method and device for producing water having absorbed wave motion energy peculiar to a color |
| 10/04/2001 | EP1137411A1 Palladium-substituted bacteriochlorophyll derivatives and use thereof |
| 10/04/2001 | EP0529002B1 Fluorescent porphyrin, and fluorescent phthalocyanine - polyethylene glycol, polyol, and saccharide derivatives as fluorescent probes |
| 10/04/2001 | CA2404712A1 Synergistic methods and compositions for treating cancer comprising antiproliferative cytotoxic and cytostatic agents |
| 10/04/2001 | CA2402187A1 Intracorporeal medicaments comprising halogenated xanthene for photodynamic treatment of disease |
| 10/03/2001 | CN1315208A 166 HO-DTPA, its preparing method and application as liquid radiation source |
| 09/27/2001 | WO2001070735A1 Heteroaromatic compounds having two-photon absorption activity |
| 09/27/2001 | US20010025144 Gas filled liposomes and their use as ultrasonic contrast agents |
| 09/27/2001 | US20010024649 Topical treatment comprises an ester or amide lipophilic molecule capable of traversing the statum corneum and inducing immature dendritic cells to migrat to the draining lymphoid organ |
| 09/27/2001 | CA2402564A1 Heteroaromatic compounds having two-photon absorption activity |
| 09/26/2001 | EP1135160A2 Boron neutron capture therapy using pre-targeting methods |
| 09/26/2001 | EP0528991B1 Detectably labelled marker component comprising a fluorophore moiety , fluorescent probe comprising the marker component and uses thereof. |
| 09/25/2001 | US6294361 Processes for photoreactive inactivation of a virus in blood cell or coagulation factor containing compositions and use thereof for preparing compositions useful for transfusion |
| 09/20/2001 | WO2001068110A1 Method and apparatus for inducing a cellular response |
| 09/20/2001 | WO2001012263A3 Dosimetry for californium-252 brachytherapy sources and encapsulation, storage, and clinical delivery thereof |
| 09/20/2001 | US20010023363 Apparatus and method for high energy photodynamic therapy of acne vulgaris and seborrhea |